VP4.F VISTIN PHARMA ASA NK 1

Healthcare Pharmaceuticals Frankfurt Exchange
1.75 EUR
Close of Nov 12, 2026
1.58 2.06
Market cap
EUR 77.6M
P/E
13.5x
P/B
2.48x
ROE
18.8%
Dividend yield
5.29%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is VP4.F undervalued?

Graham number
Price1.75
Graham value1.44
Premium21.9%

VP4.F trades 21.9% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VISTIN PHARMA ASA NK 1 fundamental analysis

No fundamental analysis for VISTIN PHARMA ASA NK 1 yet.

VISTIN PHARMA ASA NK 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VISTIN PHARMA ASA NK 1

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.

Full company profile